Yamato: Raised the target price of China Biologic Products (01177.HK) to HK$5.6, reiterating a "buy" rating.

According to the Wisdom Finance app, Daiwa released a research report reaffirming its "buy" rating on China Biopharmaceuticals (01177.HK), with a target price raised from 4 Hong Kong dollars to 5.6 Hong Kong dollars; revenue forecast for 2025 to 2027 was raised by 1% to 2%, and earnings per share forecast was raised by 3% to 4%; revenue forecast for 2028 to 2032 was raised by 4% to 10%.